D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Materials Science D-index 101 Citations 41,547 387 World Ranking 393 National Ranking 160

Research.com Recognitions

Awards & Achievements

2018 - Fellow, National Academy of Inventors

2010 - Fellow of the American Society of Mechanical Engineers

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Biochemistry

Mauro Ferrari spends much of his time researching Nanotechnology, Nanomedicine, Nanoparticle, Drug delivery and Silicon. His work often combines Nanotechnology and Extramural studies. As part of the same scientific family, Mauro Ferrari usually focuses on Nanomedicine, concentrating on Nanocarriers and intersecting with Risk analysis.

His Nanoparticle research includes themes of Molecular targeting, Porous silicon, Endocytosis and Biodistribution. His studies deal with areas such as Cancer and Immunology as well as Drug delivery. His study in Silicon is interdisciplinary in nature, drawing from both Nanoporous, Kinetics and Mesoporous material.

His most cited work include:

  • Cancer nanotechnology: opportunities and challenges. (3445 citations)
  • Principles of nanoparticle design for overcoming biological barriers to drug delivery (2464 citations)
  • Principles of nanoparticle design for overcoming biological barriers to drug delivery (2464 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Nanotechnology, Drug delivery, Nanoparticle, Cancer research and Cancer. Mauro Ferrari specializes in Nanotechnology, namely Nanomedicine. His Drug delivery study incorporates themes from Biomedical engineering and Pharmacology, Drug.

Nanoparticle is closely attributed to Porous silicon in his research. His Cancer research research integrates issues from Cancer cell, Breast cancer, Immunology and In vivo. Mauro Ferrari interconnects Doxorubicin and Pathology in the investigation of issues within In vivo.

He most often published in these fields:

  • Nanotechnology (52.77%)
  • Drug delivery (32.23%)
  • Nanoparticle (21.16%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cancer research (18.33%)
  • Drug delivery (32.23%)
  • Cancer (15.13%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Cancer research, Drug delivery, Cancer, In vivo and Nanomedicine. His Cancer research research is multidisciplinary, incorporating elements of Chemotherapy, Doxorubicin, Cancer cell, Antigen and Immunotherapy. His Drug delivery study is focused on Nanotechnology in general.

The Nanotechnology study combines topics in areas such as Vascular compartment, Active ingredient, Multicomponent systems and Microparticle. The study incorporates disciplines such as Cell and Oncology in addition to Cancer. His Nanomedicine study combines topics from a wide range of disciplines, such as Nanocarriers, Macrophage and Biodistribution.

Between 2016 and 2021, his most popular works were:

  • Clinical Cancer Nanomedicine. (111 citations)
  • Clinical Cancer Nanomedicine. (111 citations)
  • Exosomes as Reconfigurable Therapeutic Systems (95 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Biochemistry

Mauro Ferrari focuses on Drug delivery, Cancer, Cancer research, Nanomedicine and Immunology. His Drug delivery study contributes to a more complete understanding of Nanotechnology. The various areas that Mauro Ferrari examines in his Cancer study include Survival rate, Efficacy, Tolerability and Oncology.

His research in Cancer research intersects with topics in Autophagy, Cancer cell, Doxorubicin, Molecular biology and In vivo. He has researched Nanomedicine in several fields, including Internal medicine, Engineering ethics and Biodistribution. His studies deal with areas such as Foreign Bodies, Computational biology and Liposome as well as Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Cancer nanotechnology: opportunities and challenges.

Mauro Ferrari.
Nature Reviews Cancer (2005)

5775 Citations

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Elvin Blanco;Haifa Shen;Haifa Shen;Mauro Ferrari;Mauro Ferrari.
Nature Biotechnology (2015)

2705 Citations

Nanomedicine--challenge and perspectives.

Kristina Riehemann;Stefan W. Schneider;Thomas A. Luger;Biana Godin.
Angewandte Chemie (2009)

1147 Citations

Size and shape effects in the biodistribution of intravascularly injected particles.

P. Decuzzi;B. Godin;T. Tanaka;S. Y. Lee.
Journal of Controlled Release (2010)

782 Citations

Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications

Ennio Tasciotti;Xuewu Liu;Rohan Bhavane;Kevin Plant.
Nature Nanotechnology (2008)

690 Citations

Clinical proteomics: Written in blood

Lance A. Liotta;Mauro Ferrari;Emanuel Petricoin.
Nature (2003)

616 Citations

Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions

Alessandro Parodi;Nicoletta Quattrocchi;Nicoletta Quattrocchi;Anne L. van de Ven;Ciro Chiappini.
Nature Nanotechnology (2013)

596 Citations

Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?

Paolo Decuzzi;Renata Pasqualini;Wadih Arap;Mauro Ferrari;Mauro Ferrari.
Pharmaceutical Research (2009)

591 Citations

Nanotechnologies for biomolecular detection and medical diagnostics

Mark Ming Cheng Cheng;Giovanni Cuda;Yuri L. Bunimovich;Marco Gaspari.
Current Opinion in Chemical Biology (2006)

554 Citations

XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway

Xi Chen;Dimitrios Iliopoulos;Dimitrios Iliopoulos;Qing Zhang;Qianzi Tang;Qianzi Tang.
Nature (2014)

524 Citations

Best Scientists Citing Mauro Ferrari

Tejal A. Desai

Tejal A. Desai

University of California, San Francisco

Publications: 82

Hélder A. Santos

Hélder A. Santos

University of Helsinki

Publications: 77

Paolo Decuzzi

Paolo Decuzzi

Italian Institute of Technology

Publications: 65

Robert Langer

Robert Langer

MIT

Publications: 64

Ermei Mäkilä

Ermei Mäkilä

University of Turku

Publications: 59

Xiaoyuan Chen

Xiaoyuan Chen

National University of Singapore

Publications: 57

Jouni Hirvonen

Jouni Hirvonen

University of Helsinki

Publications: 56

Omid C. Farokhzad

Omid C. Farokhzad

Harvard Medical School

Publications: 55

Jarno Salonen

Jarno Salonen

University of Turku

Publications: 50

Nicolas H. Voelcker

Nicolas H. Voelcker

Commonwealth Scientific and Industrial Research Organisation

Publications: 45

Chunying Chen

Chunying Chen

Chinese Academy of Sciences

Publications: 43

Michael J. Sailor

Michael J. Sailor

University of California, San Diego

Publications: 42

Lance A. Liotta

Lance A. Liotta

George Mason University

Publications: 40

Liangfang Zhang

Liangfang Zhang

University of California, San Diego

Publications: 39

Emanuel F. Petricoin

Emanuel F. Petricoin

George Mason University

Publications: 37

Paolo A. Netti

Paolo A. Netti

Italian Institute of Technology

Publications: 35

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.